

ASX Announcement and Media Release

Friday 7 February 2003

SciGen Limited

SCI GEN ENTERS COMMERCIALISATION AGREEMENT FOR INSULIN IN INDONESIA

The Directors of SciGen Limited ("SciGen") announced today that the company has entered into a commercialisation agreement with PT Kalbe Farma Tbk. ("Kalbe") for the marketing, sale and distribution of SciGen's human insulin throughout Indonesia.

The agreement is on a non-exclusive basis for 10 years which allows SciGen to engage other distribution partners in Indonesia if it so wishes.

Kalbe is a publicly listed company in Indonesia with a current market capitalisation of US\$117 million and employs over 5,000 staff.

Kalbe is also a licensee for other major pharmaceutical companies such as Bristol Myers, Baxter, Pfizer and Schering Plough. Kalbe's annual pharmaceutical sales are in excess of US\$280 million.

The Agreement with Kalbe is expected to generate over US\$1.5 million dollars in revenues over the next three years with minimum order provisions. It is anticipated that registration of SciGen's insulin in Indonesia will take about 9 months.

The relationship that has been formed with Kalbe has the potential to cover other products in SciGen's portfolio in due course.

The agreement between SciGen and Kalbe is another example of SciGen's ability to work in the Asia Pacific Region to establish partnerships in order to maximise sales and marketing opportunities for SciGen's portfolio of products.

About SciGen

SciGen Ltd is a progressive biotechnology/biopharmaceutical company involved in co-developing and marketing genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen has acquired the rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio

currently includes proprietary biotechnology-derived products, and biogeneric products, which allows for faster entry into the

market, as the biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's major strength lies in its ability to recognise the potential of new products in their early stages of development. Through joint collaboration with its strategic partners, SciGen uses its extensive expertise in regulatory and clinical environments, in conjunction with marketing and promotional infrastructure, to bring to market products which will have significant long-term benefit.

SciGen's business was established in 1988. SciGen is a Singaporean biotechnology company, publicly listed on the Australian Stock Exchange (ASX code SIE). SciGen's headquarters is in Singapore and it also has offices in Australia, USA, Korea, Vietnam, Hong Kong and Philippines.

=====**ENDS**=====

Media enquiries

Mark Compton

Managing Director & CEO

Telephone: +61 2 9234 1700

Web: www.scigen.com.au